<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945150</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002051</org_study_id>
    <secondary_id>Merck MISP 54841</secondary_id>
    <nct_id>NCT02945150</nct_id>
  </id_info>
  <brief_title>Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant</brief_title>
  <official_title>A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof of concept, open-label single center study for the donation of HCV positive kidneys to
      HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission
      upon transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to determine if the administration of grazoprevir and elbasvir (with
      or without ribavirin) for 12-16 weeks after kidney transplantation prevents the spread of HCV
      infection from a donor kidney with known HCV genotype 1 or 4 infection to a HCV negative
      recipient as evidenced by a negative HCV viral RNA at 12 weeks post treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Negative HCV viral RNA at 12 weeks after the last dose of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of grazoprevir and elbasvir (with or without ribavirin) in patients who have undergone kidney transplantation</measure>
    <time_frame>Upto 16 weeks</time_frame>
    <description>Safety and tolerability of grazoprevir and elbasvir in the kidney transplant patient will be monitored by quantifying the number of treatment related adverse events per patient and evaluating out of range laboratory results as compared to baseline/pretreatment values per patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Treatment with grazoprevir plus elbasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 to 16 weeks of treatment with grazoprevir plus elbasvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>grazoprevir plus elbasvir (fixed dose combination)</intervention_name>
    <description>HCV treatment for 12 to 16 weeks. Treatment length based upon presence of baseline resistance associated variant in the HCV virus</description>
    <arm_group_label>Treatment with grazoprevir plus elbasvir</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must meet MGH transplant center criteria and already be listed for isolated kidney
             transplant

          2. No available living kidney donor

          3. Has ≤ 730 days (two years) of accrued transplant waiting time if blood type A and ≤
             1095 days of accrued transplant waiting time if blood type B or O.

          4. On chronic hemodialysis or peritoneal dialysis or has a glomerular filtration rate
             &lt;15mL/min/1.73m2 at the time of screening

          5. Weight ≥ 50kg

          6. Serum ALT within normal limits

        Exclusion Criteria:

          1. AB blood type

          2. BMI &gt; 35

          3. History of liver disease

          4. Pregnant or nursing (lactating) women

          5. Cardiomyopathy (LV ejection fraction &lt; 50%)

          6. Positive crossmatch or positive donor specific antibodies

          7. HIV positive

          8. HCV RNA positive

          9. HBV surface antigen positive

         10. Any contraindication to kidney transplant per MGH center protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital (Partners Healthcare)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raymond T Chung, MD</last_name>
    <phone>6177247562</phone>
    <email>rchung@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenna L Gustafson, MS</last_name>
    <phone>6177243836</phone>
    <email>JLGustafson@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Chute, BA</last_name>
      <email>LiverResearchGroup@partners.org</email>
    </contact>
    <investigator>
      <last_name>Raymond T Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meghan E Sise, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010 May;10(5):1238-46. doi: 10.1111/j.1600-6143.2010.03091.x. Epub 2010 Mar 26.</citation>
    <PMID>20353475</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond T. Chung, MD</investigator_full_name>
    <investigator_title>Director, Hepatology, Massachusetts General Hospital</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>renal failure</keyword>
  <keyword>kidney transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with study sponsor and with the hopes of publication.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

